“…From an initial 125 identified manuscripts, all the retrieved titles and abstracts were screened to discard repeated articles, leading to a total of 52 evaluable papers: 31 papers relating to Actim® PROM, 11 papers relating to AmniSure®, and 10 referring to both biomarkers. After a detailed process of selection (Figure 1 ), 35 papers were excluded because: they did not evaluate the specific biomarkers as a rapid test for PROM diagnosis [ 14 , 17 - 19 ], they studied the concentration of the biomarkers through pregnancy [ 11 , 20 - 23 ] or after an amniocentesis [ 24 ], they were solely studies of biochemical processes [ 25 , 26 ], they were adjunct to a genetic study [ 27 ], they comprised guidelines [ 9 ], they were review articles [ 8 , 13 , 28 , 29 ], they were a meta-analysis [ 30 ] or letter/comments on other articles [ 15 , 31 - 33 ], and they related to the application of the biomarker in obstetrics [ 18 , 23 ]. In two cases, the full text version of the studies were not available for consultation [ 34 , 35 ].…”